VTRS Q2 2021 Earnings — Viatris Inc. Revenue & Financial Results | Market Cap Arena

VTRSViatris Inc.

$17B

Q2 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$4.6B+67.6% YoY

Gross Profit

$1.3B29.0% margin

Operating Income

-$48M-1.0% margin

Net Income

-$279M-6.1% margin

EPS (Diluted)

$-0.23

QoQ Revenue Growth

+3.3%

Cash Flow

Operating Cash Flow

$559M

Free Cash Flow

$470M

Stock-Based Comp.

$31M

Balance Sheet

Total Assets

$58.0B

Total Liabilities

$36.8B

Stockholders' Equity

$21.2B

Cash & Equivalents

$674M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4.6B	$2.7B	+67.6%
Gross Profit	$1.3B	$1.0B	+29.4%
Operating Income	-$48M	$134M	-135.6%
Net Income	-$279M	$39M	-808.6%

Revenue Segments

Brands

$2.7B59%

Generics

$1.5B33%

Complex GX and Biosimilars

$333M7%

Geographic Segments

Developed Markets Segment

$2.6B58%

Emerging Markets Segment

$870M19%

Greater China Segment

$550M12%

Japan, Australia and New Zealand Segment

$501M11%